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Introduction
Prostaglandin E2 (PGE2) is produced during inflam-
matory responses, and increased levels of PGE2 help
mediate some of the cardinal features of inflammation,
including pain, edema, and fever (1, 2). PGE2 exerts its
effects through interactions with EP receptors, termed
EP1–4 (3). Nonsteroidal anti-inflammatory drugs
(NSAIDs) act by inhibiting cyclooxygenase (COX)
enzymes and thereby inhibiting prostaglandin pro-
duction. In the context of this putative mechanism of
action, direct cause-and-effect relationships between
interruption of specific receptor-mediated signaling
pathways and therapeutic actions have not been firm-
ly established. While NSAIDs are effective analgesic
agents, certain NSAIDs have a number of troublesome
side effects that are due in part to their broad inhibi-
tion of a variety of COX products (4, 5).
Defining the molecular mechanisms underlying
both the therapeutic and adverse actions of NSAIDs
should provide useful targets for new, more specific
therapeutic strategies. Therefore, we focused on a
receptor for one of the prostaglandins (PGE2), the EP1
receptor (6). We generated EP1-deficient mice by gene
targeting and compared their physiological responses
to genetically matched wild-type controls. We find
that EP1–/– animals have reduced nociceptive pain per-
ception as well as altered cardiovascular homeostasis.
These results demonstrate the critical actions of EP1
receptors in two physiological functions: pain percep-
tion and blood pressure regulation.
Methods 
EP1 targeting vector construction and production of EP1–/–
mice. Mouse genomic clones containing Ptgerep1,
mouse gene symbol for EP1 receptor, were isolated
from a DBA/1lacJ genomic λ-phage library (Stratagene,
La Jolla, California, USA). Long-template PCR was used
to amplify 5′and 3′ fragments of the clone using T3 or
T7 and EP1-specific primers. A 4.5-kb 5′ fragment and
6.0-kb 3′ fragment were cloned into pCRII vector (Invit-
rogen Corp., San Diego, California, USA). These frag-
ments were sequence confirmed and subcloned into
pHok, a plasmid containing PGK-neo and PGK-thymi-
dine kinase cassettes. The EP1 targeting vector was
designed to replace 671 bp of coding sequence with the
PGK-neo cassette. This 671-bp coding region was
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The lipid mediator prostaglandin E2 (PGE2) has diverse biological activity in a variety of tissues. Four
different receptor subtypes (EP1–4) mediate these wide-ranging effects. The EP-receptor subtypes dif-
fer in tissue distribution, ligand-binding affinity, and coupling to intracellular signaling pathways. To
identify the physiological roles for one of these receptors, the EP1 receptor, we generated EP1-deficient
(EP1–/–) mice using homologous recombination in embryonic stem cells derived from the DBA/1lacJ
strain of mice. The EP1–/– mice are healthy and fertile, without any overt physical defects. However,
their pain-sensitivity responses, tested in two acute prostaglandin-dependent models, were reduced
by approximately 50%. This reduction in the perception of pain was virtually identical to that achieved
through pharmacological inhibition of prostaglandin synthesis in wild-type mice using a cyclooxyge-
nase inhibitor. In addition, systolic blood pressure is significantly reduced in EP1 receptor–deficient
mice and accompanied by increased renin-angiotensin activity, especially in males, suggesting a role
for this receptor in cardiovascular homeostasis. Thus, the EP1 receptor for PGE2 plays a direct role in
mediating algesia and in regulation of blood pressure.
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cloned into pCRII for subsequent expression analysis
(see below). DBA1/lacJ embryonic stem cells (ES cells)
were grown, transformed, and screened using standard
techniques (7). Colonies in which the plasmid had inte-
grated by homologous recombination were identified
using Southern blot analysis with a 2.2-kb XbaI/SacI
probe that was external to the targeting construct. Tar-
geted ES cells were introduced into blastocysts from
C57BL/6 mice using established techniques (8). Male
chimeras were mated with DBA/1lacJ females, and the
targeted EP1 allele was detected in offspring of these
crosses using Southern blot analysis of genomic DNA
isolated from tail biopsies. Offspring carrying the
mutant allele were intercrossed to obtain inbred
DBA/1lacJ-strain mice that were homozygous for the
targeted mutation (EP1–/–). Animals were housed in
microisolator cages in a pathogen-free barrier facility.
All experimentation was performed under approved
institutional guidelines.
RNA expression analysis. Kidneys, lungs, and uteri were
harvested from EP1+/+ and EP1–/– mice, and total RNA
was extracted from the tissues using TRIzol reagent
(Life Technologies Inc., Rockville, Maryland, USA). The
SuperScript Preamplification System kit (Life Tech-
nologies Inc.) was used to generate first-strand cDNA
from each tissue by using 1 µg of RNA and oligonu-
cleotide dT in the presence of reverse transcriptase at
42°C for 1 hour. EP1 PCR was performed using oligos
EP1-90F (5′ AACCTGAGCCTAGCGGATGAGG 3′) and
EP1-807R (5′ TTCGGAATCGTCGAGAGCGACG 3′) and 
2 µl of the RT reaction as template. EP1 PCR cycling
conditions were: 94°C for 3 minutes for 1 cycle; 94°C
for 15 seconds, 61°C for 15 seconds, 72°C for 2 min-
utes for 40 cycles; 72°C 10 minutes for 1 cycle. The
expected fragment size for the EP1-90F and EP1-807R
oligonucleotide set was 717 bp. RNA integrity for each
sample was checked using a mouse β-actin oligonu-
cleotide set (CLONTECH Laboratories Inc., Palo Alto,
California, USA), following manufacturer’s recom-
mendations. There was no detectable product in the
absence of reverse transcriptase followed by PCR (data
not shown). In situ hybridization was performed on
kidney sections as described previously using the 671-
bp murine EP1 digoxigenin probe (9).
Expression of PKN in EP1–/– animals. Brain lysates (10 µg)
were prepared from EP1-deficient animals and EP1+/+
controls, suspended in RIPA buffer, resolved by 10- to
20%-gradient SDS-PAGE, and transferred onto PVDF
membrane. The primary and secondary Ab’s were pur-
chased from Santa Cruz Biotechnology Inc. (Santa Cruz,
California, USA). Western blot analysis was performed
according to the manufacturer’s protocol using PKN 
C-19 rabbit polyclonal Ab (1 µg/ml dilution) followed by
a goat anti-rabbit horseradish peroxidase–conjugated
(HRP-conjugated) secondary Ab (1:1000 dilution) and
processing of the blot using chemiluminescence.
Nociception assays. In a series of assays testing sensi-
tivity to inflammatory pain, we compared nociceptive
responses in EP1–/– mice and controls consisting of
EP1+/+ or EP1+/– mice. All mice were fasted overnight
before the experiments, and assays performed were
blind to EP1 genotypes.
For the acetic acid experiments, 16 µl/g body weight
of 0.7% acetic acid in water was administered by
intraperitoneal injection. The mice were placed in 1 L
(inner volume) clear glass beakers, and the number of
stretches was counted for 20 minutes beginning imme-
diately after acetic acid treatment. In separate groups
of EP1+/+ and EP1–/– mice, the COX inhibitor, piroxicam
(5 mg/kg), was administered 30 minutes before acetic
acid injection. The piroxicam was dissolved in 0.1%
methylcellulose and 0.9% NaCl and was administered
by subcutaneous injection.
For the 2-phenyl-1, 4-benzoquinone–induced (PBQ-
induced) stretch assays, 0.2% 2-phenyl-1, 4-benzo-
quinone was dissolved in 5% ethanol, and 15 µl/g body
weight was injected intraperitoneally. Beginning 5
minutes after PBQ injection, stretching responses were
assessed for 10 minutes.
Measurement of PGE2 and 6-keto-PGF1α in peritoneal
fluid. After acetic treatment, prostaglandin concentra-
tions were derived from peritoneal fluid after lavaging
the peritoneal cavity with 900 µl sterile PBS immedi-
ately after behavioral observations. PGE2 and 6-keto-
PGF1α (PGI2 stable metabolite) levels were quantified
using the scintillation proximity assay method (Amer-
sham Pharmacia Biotech Inc., Piscataway, New Jersey,
USA), according to the manufacturer’s instructions.
Systolic blood pressure measurements in conscious mice.
Systolic blood pressure was measured in conscious
mice as described previously with a computerized tail-
cuff system (Visitech Systems, Apex, North Carolina,
USA) that determines systolic blood pressure using a
photoelectric sensor (10). This system allows pressures
to be measured in four mice simultaneously and min-
imizes the potential for observer bias. Before the study
was initiated, mice were adapted to the apparatus for
at least 5 days. The validity of this system has been
established previously, and we have demonstrated its
correlation with intra-arterial pressure measurements
in several experimental systems (11). To determine the
effects of the EP1 gene disruption on the adaptation
to changes in dietary salt intake, we measured systolic
blood pressures in mice that were sequentially fed diets
of different sodium chloride content (Harlan-Teklad
Laboratory, Madison, Wisconsin, USA). EP1+/+ and
EP1–/– mice were first fed a control diet containing
0.4% sodium chloride. This was followed by a 10-day
period in which the animals were fed a low-salt diet
containing less than 0.02% sodium. Throughout the
period of study, mice were allowed free access to water,
and systolic blood pressures were measured at least
five times per week.
Renin mRNA expression. To examine the effects of the
EP1 mutation on the renin-angiotensin system, we ana-
lyzed kidney renin mRNA expression in whole kidney
using a ribonuclease assay as described previously (12).
To estimate the concentration of renin mRNA in each
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sample, a standard curve was constructed by hybridiz-
ing a renin probe with known quantities of renin cDNA
that had been transcribed in vitro. Renin mRNA levels
are expressed in picograms of renin mRNA per micro-
gram of total kidney RNA.
Plasma renin activity. Following exposure of mice to
CO2 vapors, blood was drawn from the renal artery and
collected in EDTA-coated tubes in less than 30 seconds.
Plasma was isolated and stored at –70°C until the assay
was performed. Plasma renin activity was determined
using radioimmunoassay, according to the manufac-
turer’s protocol (NEN Life Science Products Inc.,
Boston, Massachusetts, USA).
Data analysis. The values for each parameter within a
group are expressed as the mean ± SEM. For compar-
isons between EP1–/– and control groups statistical sig-
nificance was assessed using Student’s t tests.
Animal handling. Animals were housed in microisola-
tor cages in a pathogen-free barrier facility. All experi-
mentation was performed under approved protocols by
the Pfizer Global Research and Development Institu-
tional Animal Care and Use Committees.
Results
Generation of EP1–/– mice. The lack of potent and specif-
ic agonists and antagonists of the individual EP-recep-
tor subtypes that are suitable for in vivo experiments
has been an impediment to defining their distinct
functions. To directly examine the role of PGE2 acting
through the EP1 receptor in physiological responses,
including pain perception, we generated EP1 recep-
tor–deficient mice by gene targeting in ES cells from
DBA/1lacJ inbred mice (13, 14). To produce a null
mutation in the EP1-receptor gene, a replacement con-
struct was designed that deletes 671 bp of the EP1-cod-
ing sequence from exon 2 (Figure 1a). The construct
was introduced into the DBA/1lacJ ES cell line by elec-
troporation, and six correctly targeted cell lines were
identified by using Southern blot analysis. ES cells
from two EP1-targeted lines were microinjected into
C57BL/6J blastocysts, and three DBA/1lacJ-C57BL/6
chimeric male mice were generated. The chimeras were
crossed with DBA/1lacJ females to establish germline
transmission and to maintain the DBA/1lacJ inbred
background of the mice bearing the EP1 mutation.
The Journal of Clinical Investigation | February 2001 | Volume 107 | Number 3 327
Figure 1
Generation of PGE2 EP1 receptor–deficient DBA/1lacJ mice. (a) Strategy to inactivate EP1 by homologous recombination in DBA/1lacJ ES
cells. Restriction maps depicting EP1 gene-targeting vector (top), endogenous EP1 gene (middle), and the targeted EP1 allele (bottom) are
shown. Restriction enzymes used for mapping were: B, BamH1; E, EcoR1; H, HindIII; K, Kpn1; S, SacI; Sp, Spe1; and X, XbaI. PGK-tk and
PGK-neo were inserted in opposite orientation to the EP1 gene as depicted in targeting vector (top). (b) Southern blot analysis of EP1+/+
(wild-type), EP1+/– (heterozygotes), and EP1–/– (homozygous mutants) genotypes. Genomic DNA from mouse tail was isolated and digest-
ed with BamH1 and hybridized with the external XbaI/SacI probe. The insertion of the neomycin gene into the EP1 locus produces a shift
from the approximately 20-kb endogenous BamH1 fragment to 12 kb. (c) Expression of EP1 mRNA in EP1–/– and EP1+/+ mice by RT-PCR
analysis of lung (L), uterus (U), and kidney (K) RNA. Positive PCR product was observed in tissues from EP1+/+ mice; however, none was
present in EP1–/– mouse tissues, confirming loss of EP1 expression. β-actin controls were performed confirming presence of intact RNA in
all samples. (d) Western blot analysis of PKN expression in brain lysates isolated from EP1–/– (left) and EP1+/+ (right) mice demonstrates
that brain PKN protein levels are not affected by the targeting of ptgerep1. (e) In situ hybridization of kidney sections from EP1+/+ (left) and
EP1–/– (right) mice demonstrates EP1-specific (not PKN) tubular expression.
Homozygous EP1–/– mice were generated by inter-
crossing EP1+/– heterozygotes (Figure 1b). Among the
first 95 progeny of these heterozygous crosses, only 13 of
95 (13.7%) were EP1–/–, significantly fewer than the 25%
predicted by simple Mendelian inheritance. However,
when EP1-deficient mice were produced by crossing
EP1–/– and EP1+/– animals, the expected 50:50 ratio of
EP1+/– and EP1–/– progeny was observed (56 and 52,
respectively). Thus, unlike other mouse lines with tar-
geted mutations in genes in the COX pathway, such as
the FP receptor (15), the EP2 receptor (16, 17), or COX-2
(18, 19), the absence of the EP1 receptor does not cause
marked alteration in reproductive functions. The EP1–/–
animals were normal in appearance and could not be dis-
tinguished from their wild-type littermates by simple
observation. Furthermore, no histopathological changes
were observed in 39 tissues from EP1–/– male and female
mice, including the adrenal gland, brain (cerebrum, cere-
bellum, pons), bone marrow, cecum, colon, duodenum,
epididymis, esophagus, eyes, femur, harderian gland,
heart, gall bladder, ileum, jejunum, liver, lung, mamma-
ry gland, mesenteric lymph nodes, ovaries, pancreas,
pituitary gland, prostate, salivary gland, seminal vesicle,
skin, spinal cord, spleen, sternum, stomach, testes, thy-
mus, thyroid gland, trachea, urinary bladder, uterus, and
vagina. Importantly, kidneys from EP1-deficient mice
appeared structurally normal with no evidence of the
glomerular and renal cortical abnormalities that were
described previously in COX-2–deficient mice (18, 19).
To verify that the targeted mutation introduced into
the EP1 gene locus (ptgerep1) resulted in complete inac-
tivation of the gene, we examined expression of EP1-
receptor mRNA by RT-PCR and in situ hybridization in
tissues known to express EP1 receptors. EP1 mRNA was
not detected in the kidney, lung, or uterus by RT-PCR
analysis in tissues isolated for EP1 receptor–deficient
mice (Figure 1c). It has been suggested that the ptgerep1
locus may overlap with a gene encoding protein kinase
N, PKN (20). Based on the deduced sequences, the muta-
tion induced in the ptgerep1 locus lies within the 3′
untranslated region of the PKN gene. To determine
whether the targeted mutation altered expression of
PKN, we measured PKN protein levels using Western
blot analysis. Because previous studies have document-
ed expression of PKN in the brain and kidney, protein
lysates of these tissues were prepared from EP1–/– and
EP1+/+ animals. PKN protein was not detected in kidney
lysates from either wild-type or EP1-deficient animals
(data not shown). However, as shown in Figure 1d, PKN
protein was easily detected in brain lysates from wild-
type animals. Abundant PKN expression was also seen
in the EP1-deficient animals, and there was no difference
in the levels of PKN expression between EP1+/+ and EP1–/–
animals. In situ hybridization using an EP1
receptor–specific probe showed a complete absence of
detectable signals in EP1–/– kidneys (Figure 1e) consis-
tent with the results obtained from the PKN protein
analysis in EP1–/– and EP1+/+ tissues.
Reduced nociceptive perception in EP1-deficient animals
(acetic acid–induced stretch model). During an inflammato-
ry response, pain is produced through complex interac-
tions between a number of inflammatory mediators that
are released at the site of injury or insult (21, 22). To
understand the specific role of the EP1 receptor in medi-
ating pain responses, we tested EP1–/– mice using estab-
lished models of algesia (23). We first compared acetic
acid–induced stretching in inbred DBA/1lacJ EP1+/+ and
EP1–/– mice. As depicted in Figure 2a, injection of acetic
acid into the peritoneum of wild-type mice induced sig-
nificant stretching behavior with a mean of 16 stretches
over the first 20 minutes after injection (median = 17). In
EP1-deficient mice, acetic acid–induced stretching was
significantly reduced to a mean of eight stretches over 20
minutes (median = 9; P < 0.01 versus EP1+/+).
To determine whether differences in prostanoid pro-
duction might explain the amelioration of pain in the
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Table 1
Comparison of PGE2 and the stable PGI2 metabolite peritoneal-fluid
levels in EP1+/+ and EP1–/– after treatment with acetic acid
PGE2 (ng/ml) 6-keto PGF1α (ng/ml)
EP1+/+A 13.6 ± 1.4 49.7 ± 3.3
EP1–/–B 18.3 ± 3.2 62.1 ± 6.1
An = 8; Bn = 7
Figure 2
Nociceptive responses in EP1 receptor–deficient mice. (a)
Acetic acid–induced stretching. The number of stretches
was counted for 20 minutes immediately after 0.7% acetic
acid injection intraperitoneally. Piroxicam (5 mg/kg subcu-
taneously) or vehicle was administered 30 minutes before
acetic acid treatment. n = 8 for each group. AP < 0.01. (b)
PBQ-induced stretching. Stretching behaviors were induced
by injection of 0.02% PBQ intraperitoneally. The number of
stretches was counted from 5 to 15 minutes after PBQ
treatment. n = 9 EP1+/– (filled bar) and n = 11 EP1–/– (open
bar) mice. AP < 0.05.
EP1–/– animals, we compared the concentrations of
PGE2 and prostacyclin (PGI2) in peritoneal fluid from
wild-type and EP1-deficient mice. There were no dif-
ferences in the concentration of PGE2 or PGI2 in peri-
toneal lavage fluid from EP1–/– and EP1+/+ mice after
administration of acetic acid (Table 1).
To test the relative activities of other prostaglandins
in this model, separate groups of wild-type and EP1-
deficient mice were treated with the COX inhibitor,
piroxicam (24), before administration of acetic acid. In
wild-type mice, pretreatment with the NSAID piroxi-
cam reduced acetic acid–induced stretching to a mean
of seven stretches in 20 minutes (P < 0.01 versus EP1+/+
without piroxicam); this inhibition of pain sensation is
virtually identical to that of EP1–/– mice that did not
receive piroxicam (Figure 2a). In contrast, piroxicam
treatment did not significantly alter acetic acid–induced
stretching in the EP1–/– mice (P = 0.15 versus EP1–/–
without piroxicam) (Figure 2a). Thus, the absence of the
EP1 receptor was associated with a 50% reduction in
pain sensitivity compared with controls. In this model,
the lowering of pain responses in the EP1-deficient mice
was equivalent to that achieved by COX inhibition in
wild-type mice, suggesting that a significant portion of
the actions of NSAIDs in reducing pain responses
involves inhibition of EP1 signaling. Despite the signif-
icant diminution of pain sensitivity with EP1 deficien-
cy or piroxicam administration, there is still a persistent
response confirming the presence of other, non-
prostaglandin, mediators of pain in this model.
Reduced nociceptive perception in EP1 receptor–deficient
mice (PBQ-induced stretch model). As a second measure of
inflammatory nociception, we evaluated responses in
the PBQ-induced stretching assay (23) (Figure 2b). In
control animals, injection of PBQ induced a mean of
10 stretches in 10 minutes (median = 11). In contrast,
the mean number of PBQ-induced stretches was only
five in EP1–/– mice (P < 0.05 versus controls). Thus, the
absence of the EP1 receptor was associated with a sim-
ilar degree of amelioration of PBQ-induced stretching
(50%), as was observed in the acetic acid model.
Systolic blood pressure is significantly reduced in EP1 recep-
tor–deficient mice. Along with its role as an inflammato-
ry mediator, PGE2 has vascular actions that may con-
tribute to the control of both systemic and regional
hemodynamics (25). Based on its effects on vascular
resistance and renal sodium excretion, a role
for PGE2 in blood pressure homeostasis has
been suggested (26). Furthermore, aggrava-
tion of blood pressure control has been
reported as a complication of chronic treat-
ment with NSAIDs (27).
To assess the role of the EP1 receptor in the
regulation of blood pressure, we examined the
functional consequences of EP1-receptor
inactivation on blood pressure. Systolic blood
pressure was measured in conscious mice
using an automated tail-cuff manometer sys-
tem. Resting blood pressure was significantly
lower in a mixed group of male and female EP1-deficient
mice (114 ± 3 mmHg; n = 18) compared with controls
(122 ± 2 mmHg; n = 16, P < 0.05). Because we had found
previously that the contribution of individual EP-recep-
tor subtypes to the regulation of vascular tone differs dra-
matically between males and females (28), we next ana-
lyzed blood pressure in separate groups of male and
female EP1–/– mice compared with male and female wild-
type controls. Systolic blood pressures were more than 10
mmHg lower in male EP1–/– mice compared with male
controls (Figure 3). While blood pressures also tended to
be lower in female EP1–/– mice (105 ± 3 mmHg; n = 6)
than controls (112 ± 4 mmHg; n = 6), this difference did
not achieve statistical significance (P = 0.19).
Cardiovascular regulation in EP1–/– mice. The low blood
pressures in male EP1–/– mice triggered physiological
compensatory responses. First, pulse rates were signifi-
cantly increased in male EP1–/– (732 ± 7 beats/minute; 
n = 10) mice compared with male EP1+/+ animals (694 ±
9 beats/minute; n = 10, P < 0.01). Second, kidney renin
mRNA levels and plasma renin activity were signifi-
cantly elevated in male EP1–/– mice compared with male
wild-type controls, but not females (Table 2). These are
typical responses to reductions in blood pressure
and/or extracellular fluid volume. To explore this issue
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Table 2
Male EP1–/– mice, but not female EP1–/– mice, have elevated renin-angiotensin
activity as compared with their EP1+/+ controls
Plasma renin Kidney renin Plasma angiotensinogen 
concentration PRA mRNA level Agt 
(AngI ng/ml/h) (pg/mg total RNA) (AngI ng/ml/h)
EP1+/+ males 38.8 ± 6.1A 38.5 ± 2.2 261.1 ± 12.2B
EP1–/– males 85.6 ± 10.3 38.6 ± 0.6 325.0 ± 8.0
EP1+/+ females 215.3 ± 21.4 68.1 ± 4.9 262.6 ± 7
EP1–/– females 196.9 ± 21.2 80.2 ± 3.1 255.3 ± 14.1
AP < 0.01. BP < 0.05.
Figure 3
The absence of EP1 receptors causes significant changes in cardio-
vascular homeostasis. Resting systolic blood pressure was meas-
ured by tail-cuff manometry as described in Methods. Data shown
are the average ± SEM (millimeters of mercury) of 5 consecutive
days of training followed by 5 consecutive days of measurements.
Ten males of each genotype were used for the recordings. (Normal
sodium diet: EP1–/–, 111 ± 4 mmHg; EP1+/+, 122 ± 2 mmHg. Low-
sodium diet: EP1–/–, 103 ± 4 mmHg; EP1+/+, 111 ± 4 mmHg.) 
AP < 0.05 Student’s unpaired t test.
further, we monitored blood pressures in male EP1–/–
and EP1+/+ mice during feeding of a standard diet con-
taining 0.4% (wt/wt) sodium chloride followed by a diet
with a very low-sodium content (<0.02% wt/wt). Systolic
blood pressures were virtually identical in the wild-type
animals on the control (122 ± 2 mmHg; n = 10) and low-
sodium diets (119 ± 2 mmHg; n = 10). In contrast, mean
systolic blood pressures decreased by an additional 8
mmHg in the male EP1–/– mice (n = 10) on the low-salt
diet (Figure 3) (P = 0.062 versus EP1–/– on control diet,
using paired Student’s t test; P = 0.008 versus male
EP1+/+ on low-salt diet using unpaired Student’s t test).
Thus, the EP1 receptor plays a key role in regulating
blood pressure, especially in males.
Discussion
Our experiments identify critical actions of the EP1
receptor in acute, prostaglandin-dependent pain
responses. In the acetic acid model, our studies indicate
that inhibition of signaling through the EP1 receptor
accounts for a major component of the effect of
NSAIDs to ameliorate pain. Studies by Murata and col-
leagues using mice lacking prostacyclin receptors (IP)
have also suggested that IP receptors play a large role in
this response (29). While the reasons for these differing
results are not clear, variation in the genetic back-
ground of the mice is one factor that may contribute.
Background genes have profound effects on the phe-
notype of other EP receptor–deficient mice (9). How-
ever, if genetic background affects pain responses to
prostaglandins, one must be concerned about poten-
tially confounding effects caused by the mixed genetic
background of the IP-receptor knockouts. By contrast,
the EP1-deficient mice were produced on an inbred
DBA/1lacJ background. Recent studies in which PGE2
and PGE analogues were microinjected into the rat ven-
tromedial hypothalamus are also consistent with a role
for EP1 receptors in the antinociceptive actions of
PGE2 (30). Alternatively, it is possible that signals from
both the EP1 and IP receptors are involved in the acetic
acid response and that the absence of either receptor
alone is sufficient to attenuate the response. The obser-
vation that IP and EP1 receptors are coexpressed in
dorsal root ganglia provides theoretical support for
this possibility (31). Taken together, these data indicate
that the EP1 receptor, along with IP receptors, are
potential therapeutic targets for ameliorating inflam-
matory pain. There is a substantial body of evidence
that supports a role for PGE2 in the regulation of blood
pressure and vascular tone. Acute administration of
PGE2 causes marked vasodilation, and these hemody-
namic actions of PGE2 are probably most important
for short-term regulation of blood flow. We and others
have recently used gene targeting to define the relative
roles of EP receptors in mediating the acute vascular
actions of PGE2 (28, 32). In these studies, the EP2 and
EP4 receptors appeared to be the dominant mediators
of vasodilation. However, there were substantial differ-
ences between males and females in the contributions
of individual EP receptors to the vasodilatory response.
In particular, the EP1 receptor appears to mediate
vasodilation in males.
The chronic effects of PGE2 to influence blood pres-
sure seem to be variable. Depending on the circum-
stance and mode of administration, chronic adminis-
tration of PGE2 has been reported to either increase
(33, 34) or reduce blood pressure in vivo (28, 35). How-
ever, over the long term, actions of PGE2 to influence
sodium excretory mechanisms in the kidney should be
a critical determinant in its actions to regulate blood
pressure. In this regard, the EP1-receptor expression
has been demonstrated in mouse, rat, rabbit, and
human kidneys (36–39). Our studies demonstrate a
unique role for the EP1 receptor in blood pressure
homeostasis since the absence of EP1 receptors is asso-
ciated with significant reductions in blood pressure,
especially in males. Furthermore, our data suggest that
the absence of the EP1 receptor is associated with an
inability to maintain normal extracellular fluid volume
since pulse and plasma renin activity are elevated when
the animals are fed a “normal” 0.4% sodium diet. The
observation that there is an additional fall in blood
pressure when the animals are fed a sodium-deficient
diet is also consistent with actions of the EP1 receptor
to promote sodium reabsorption in the mouse.
Evidence from a number of sources has suggested
that mechanisms of blood pressure homeostasis might
be quite different for males and females (40, 41). For
example, in several models of hypertension, elevated
blood pressure develops sooner and is more severe in
males than females (42). In addition, experimental
studies in humans have identified significant differ-
ences between males and females in the relationship of
sodium chloride intake to alterations in blood pressure
(43–45). Our findings suggest that the EP1 receptor
may contribute to the sexual dimorphism in blood
pressure regulation. This finding is also consistent with
our previous studies demonstrating that the contribu-
tion of various EP receptors to the vasodilator actions
of PGE2 differ between sexes (28).
Inhibition of the COX pathway using gene targeting
(18, 46, 47) or pharmacological inhibitors have demon-
strated the importance of prostaglandins, and specifi-
cally PGE2, in mediating pain and/or inflammation
(48–50). We provide evidence supporting the role of the
EP1 receptor in mediating pain and inflammation. The
role of PGE2 on cardiovascular homeostasis is more
complex and is still debated as reports suggest that it
can act both as an antihypertensive or prohypertensive
hormone. This is due in part to the different EP recep-
tor–mediated signal-transduction pathways. We show
that the absence of the EP1 receptor causes a signifi-
cant decrease in systolic blood pressure in males, but
not females, and that dietary sodium restriction exac-
erbates this male-specific hypotension. The reduction
in blood pressure is accompanied by a compensatory
increase in activity of the renin-angiotensin system. In
conclusion, our data suggest that selective inhibition
330 The Journal of Clinical Investigation | February 2001 | Volume 107 | Number 3
of the EP1 receptor might inhibit pain responses while
also providing favorable cardiovascular effects.
In summary, the findings reported here suggest that
the analgesic actions of NSAIDs in inflammatory pain,
especially visceral stimuli, are mediated to a significant
degree by inhibition of signaling through the EP1
receptor. Moreover, the absence of EP1 receptors does
not cause abnormalities in kidney structure and results
in a lowering of resting blood pressure. Accordingly,
these data identify the EP1 receptor as a selective target
for therapies that would possess the analgesic effects of
NSAIDs without adverse effects on the kidney.
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